Northwestern Reports 100% One-Year Survival After Double Lung Transplant in 17 Patients With Stage 4 NSCLC Confined to Lungs

The Northwestern team selected patients after exhaustive staging confirmed no extrapulmonary disease, prior exposure to contemporary chemo-immunotherapy, and application of surgical techniques refined during COVID-era transplants. Follow-up through January 2026 showed four recurrences and two non-cancer deaths; 74 of 81 matched patients on standard therapy experienced progression. This outcome extends the precedent of liver transplant for selected hepatocellular carcinoma by demonstrating that complete organ removal can interrupt locally confined, treatment-resistant disease.

Broader eligibility shifts are already underway. Centers have quietly expanded criteria for other organ-limited malignancies, yet lung allocation remains zero-sum; each organ granted to a cancer recipient reduces availability for patients with idiopathic pulmonary fibrosis or COPD who lack malignancy. The observed trend toward earlier survival in cancer patients versus non-cancer recipients requires longer follow-up to determine whether recurrence risk eventually erodes the initial advantage.

Next steps hinge on multi-center prospective registries rather than single-site case series. Randomized allocation trials are ethically challenging, so well-powered observational studies with standardized selection protocols and five-year recurrence data will determine whether this approach enters guidelines or remains investigational.